跳至主要内容
临床试验/NCT00909129
NCT00909129已完成不适用

Hepatitis C Virus Dynamic and Immune Activation in HIV-1 Coinfected Patients Treated With Pegylated Interferon Alfa-2a and Ribavirin

Karolinska Institutet1 个研究点 分布在 1 个国家目标入组 25 人开始时间: 2009年5月27日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
25
试验地点
1
主要终点
Sustained virological response

研究概览

简要总结

The purpose of this study is to investigate T-cell mediated immune responses to HIV-1 and HCV and determine how these responses are affected by HCV treatment and correlates to response. Furthermore, to study Interferon-inducible protein-10 (IP-10) dynamics during HCV treatment, and correlate this to treatment outcome.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Basic Science
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • HIV-1 Hepatitis C coinfected adult patients
  • Hepatitis C treatment naive
  • Stable HIV-1 infection with or without cART
  • > 300 CD4+ cell count

排除标准

  • Decompensated liver disease
  • Ongoing depression
  • Ongoing drug abuse
  • Other contraindications for interferon or ribavirin treatment

研究组 & 干预措施

HIV-1 HCV coinfected patients

Experimental

HIV-1 HCV coinfected patients undergoing HCV therapy

干预措施: pegylated interferon-alpha (Pegasys) (Drug)

HIV-1 HCV coinfected patients

Experimental

HIV-1 HCV coinfected patients undergoing HCV therapy

干预措施: ribavirin (COPEGUS) (Drug)

结局指标

主要结局

Sustained virological response

时间窗: 24 weeks end of treatment (EOT)

次要结局

  • T-cell mediated immune responses(baseline to 24 weeks EOT)

研究者

申办方类型
Other

研究点 (1)

Loading locations...

相似试验